SETDB1 interactions with PELP1 contributes to breast cancer endocrine therapy resistance

SETDB1 interactions with PELP1 contributes to breast cancer endocrine therapy resistance

Background: Methyltransferase SETDB1 is highly expressed in breast cancer (BC), however, the mechanisms by which SETDB1 promotes BC progression to endocrine therapy resistance remains elusive. In this study, we examined the mechanisms by which SETDB1 contribute to BC endocrine therapy resistance. Me...

Full description

Bibliographic Details
Main Authors: Altwegg, K.A (Author), Chen, Y. (Author), Ebrahimi, B. (Author), He, Y. (Author), Lai, Z. (Author), Li, X. (Author), Liu, J. (Author), Liu, Z. (Author), Pratap, U.P (Author), Rao, M.K (Author), Sareddy, G.R (Author), Shen, L. (Author), Tang, W. (Author), Tekmal, R.R (Author), Vadlamudi, R.K (Author), Viswanadhapalli, S. (Author)
Format: Article
Language:English
Published: BioMed Central Ltd 2022
Subjects:
Akt
Breast cancer
Breast Neoplasms
breast tumor
Cell Line, Tumor
cell proliferation
Cell Proliferation
corepressor protein
Co-Repressor Proteins
drug resistance
Drug Resistance, Neoplasm
estrogen receptor
female
Female
gene expression regulation
Gene Expression Regulation, Neoplastic
genetics
histone lysine methyltransferase
Histone-Lysine N-Methyltransferase
human
Humans
metabolism
PELP1
PELP1 protein, human
protein kinase B
Proto-Oncogene Proteins c-akt
Receptors, Estrogen
Saccharomyces cerevisiae
SETDB1
SETDB1 protein, human
tamoxifen
Tamoxifen
Therapy resistance
transcription factor
Transcription Factors
tumor cell line
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items